CMCarl Johan Molin

Carl Johan Molin

*This is an algorithmically generated author record based on publicly available information.

Carl Johan Molin has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluating digital triage symptom checker with historical triage-related adverse events

    by Jonathan Ilicki, Sandra Edman, Joacim Stalfors, Carl Johan Molin

    Online symptom checkers are increasingly used for diagnostic support and triage. However, evidence on their performance and evaluations with real-world data remains limited. The aim of this study was to evaluate the performance of a digital symptom checker using clinical vignettes derived from real-world cases that had previously been incorrectly triaged. A patient-facing, rule-based digital symptom checker used in Swedish primary care was assessed in this study. Vignettes were constructed from cases reported to the Swedish Health and Social Care Inspectorate due to erroneous telephone triage. We hypothesized that the digital symptom checker could provide appropriate triage for these cases. Seven physicians independently simulated patients by entering symptoms in the symptom checker based on each vignette. Triage outcomes were assessed against the Swedish National Triage Guidelines (RGS), evaluating the accuracy and the safety of the triage recommendation. A total of 69 unique vignettes yielded 483 individual trials. After excluding 93 trials due to significant deviations from the original vignette description (adding or omitting symptoms), 390 trials were included in the primary analysis. The symptom checker achieved 91% accuracy (95% CI 88-94%) and 94% safety (95% CI 91-96%). The symptom checker demonstrated high accuracy and safety when triaging a subset of vignettes based on real-world cases that had been previously erroneously triaged. This study also highlights the difficulties of using vignettes when evaluating symptom checkers. To our knowledge, this is the first study to evaluate such systems using vignettes based on actual patient cases with known triage errors.


  • Physical exercise in myasthenia gravis is safe and improves neuromuscular parameters and physical performance-based measures: A pilot study

    by Elisabet Westerberg, Carl Johan Molin, Ida Lindblad, Margareta Emtner, Anna Rostedt Punga

    Introduction: Due to the shortage of exercise-related research in Myasthenia Gravis (MG), there are no consensus guidelines on physical exercise for MG patients. Methods: In this prospective pilot study, 10 MG patients with mild disease performed supervised aerobic and resistance training twice weekly for 12 weeks. The Myasthenia Gravis Composite (MGC) score, compound motor action potential (CMAP), repetitive nerve stimulation, muscle force, physical performance-based measures, serum levels of interleukin-6, muscle enzymes, and immuno-microRNAs miR-150-5p and miR-21-5p were assessed before and after the training period. Results: Physical exercise was well tolerated, and the MGC score was unchanged. Muscle resistance weights and CMAP amplitudes increased for biceps brachii and rectus femoris muscles, and physical performance-based measures improved. Muscle enzymes remained normal, whereas disease-specific microRNAs miR-150-5p and miR-21-5p were reduced after the training period. Conclusions: We propose that general recommendations regarding physical exercise can be applied safely to well-regulated MG patients. Muscle Nerve 56: 207–214, 2017


  • Open Access

    Profile of upregulated inflammatory proteins in sera of Myasthenia Gravis patients

    by Carl Johan Molin, Elisabet Westerberg, Anna Rostedt Punga

    This study describes specific patterns of elevated inflammatory proteins in clinical subtypes of myasthenia gravis (MG) patients. MG is a chronic, autoimmune neuromuscular disease with antibodies most commonly targeting the acetylcholine receptors (AChRab), which causes fluctuating skeletal muscle fatigue. MG pathophysiology includes a strong component of inflammation, and a large proportion of patients with early onset MG additionally present thymus hyperplasia. Due to the fluctuating nature and heterogeneity of the disease, there is a great need for objective biomarkers as well as novel potential inflammatory targets. We examined the sera of 45 MG patients (40 AChRab seropositive and 5 AChRab seronegative), investigating 92 proteins associated with inflammation. Eleven of the analysed proteins were significantly elevated compared to healthy controls, out of which the three most significant were: matrix metalloproteinase 10 (MMP-10; p = 0.0004), transforming growth factor alpha (TGF-α; p = 0.0017) and extracellular newly identified receptor for advanced glycation end-products binding protein (EN-RAGE) (also known as protein S100-A12; p = 0.0054). Further, levels of MMP-10, C-X-C motif ligand 1 (CXCL1) and brain derived neurotrophic factor (BDNF) differed between early and late onset MG. These novel targets provide valuable additional insight into the systemic inflammatory response in MG.


  • Compound Motor Action Potential: Electrophysiological Marker for Muscle Training

    by Carl Johan Molin, Anna R. Punga

    Purpose: The compound motor action potential (CMAP) represents the summated action potentials of all stimulated motor endplates and potentially reflects muscle hypertrophy and increased muscle contractions. Since electrophysiological biomarkers for high-resistance strength training are lacking, the authors evaluated whether the CMAP of distal and proximal muscles differs between healthy men and women who perform and do not perform high-resistance muscle training. Methods: Motor neurography was performed with stimulation of the median nerve (recording of abductor pollicis brevis muscle), peroneal nerve (recording of extensor digitorum brevis muscle), femoral nerve (recording of rectus femoris muscle) and musculocutaneous nerve (recording of biceps brachii muscle), and isometric muscle strength, measured with a hand-held dynamometer, were performed on 83 healthy subjects (52 women). Results: Trained women had 25% higher CMAP amplitude in the rectus femoris muscle than untrained women (P < 0.001), whereas CMAP amplitude in the trained male cohort was 25% higher in the biceps (P = 0.005) compared with untrained men. In the trained group, CMAP amplitude in the biceps correlated with isometric muscle strength (R = 0.30; P = 0.046). Conclusions: The authors' propose the CMAP as an objective neurophysiological parameter for proximal muscle status and training effects in future interventional studies of patients with neuromuscular disorders.